argenx starts Phase II for anti-CD70 mAb ARGX-110

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) began the Phase II portion of an open-label, European Phase I/II trial evaluating IV ARGX-110 every 3 weeks to treat advanced malignancies expressing CD70 (CD27L) in about 54 patients. The company expanded enrollment to include 10 additional patients with relapsed or refractory cutaneous T cell lymphoma (CTCL). The primary endpoints are safety and response rate, while secondary endpoints include pharmacokinetics and immunogenicity.

argenx expects interim data by year end and top-line data in 2H18...